Member Info for mact4

Titania

Yes I remember that too, which could imply market news to come out several weeks before
Think maybe this time they are pre- lining up the scientistists/academics to peer-review the data as soon as possible.
I seem to remember last time the delay with peer reviewing the P2 data was partially put down to academia backlog.

Personally anything beyond the end of Jan (I’ll allow a little leeway till first week if Feb) is no longer ‘Early 2022’.

Top line data should be available within these timescales. Delay beyond this timescale really does not make sense otherwise.

IMHO Both are partially correct:

Welcome to the Division of Investment
The Division of Investment, under the supervision of the State Investment Council, is one of the largest pension fund managers in the United States, responsible for the investment management of the seven pension funds that comprise the New Jersey Pension Fund and the State of New Jersey Cash Management Fund. As of the end of Fiscal Year 2020, the Pension Fund was valued at $76 billion.

Taken on its own, no not a huge significance. This holding would only gave cost the stare about £300K. Small amount.

But what it may imply … then yes.

For instance:
1) Synairgen is a small UK company . Why should the state invest in it when there are many more options Stateside?
2) Indicates their awareness of what Synairgen is doing and may have an impact on lobbying to get us past EUA approval ASAP. A positive influence
3) if I’ve state is investing what’s your say other states are not going do as well?

Etc, etc

I would certainly hope so

Bought 155K shares

What an interesting story, Tattyhead61.
Decided to look into this Heerma story - too much time on my hands atm. Turns out Heerma senior was a Waffen-SS officer who was convicted of war crimes.

Am with you in that SeaBoy aka north of £10.

I suppose if your average is below 50p or even £1, then £3 or even £5 seems a good exit price but if P3 delivers good results, with COPD, this will seriously undervalue the company. I guess it also depends how long you can keep your money invested for…

Thanks for highlighting this Brand
Had missed it the first time round - too much noise on this board.
Good to have a guided range of acceptable to good to very good results from such a respected source.

Patagucci

One of the sub-links from this thread: https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=interferon&cntry=&state=&city=&dist=&Search=Search

There are 192 studies of inteferons on this list but only one SNG001.

I looked at that list and came to appreciate the BOD even more. Data is king.

Subcutaneous application. Not SNG001.

If you look at one of the previous links - there are many interferon clinical trials at various stages and phases, but only one trial using SNG001 i.e. interferon B-1a via the inhalation route.

Apart from the pure number of hospitalised patients, there is also another number to factor in - limited supply of SNG. What do I mean? To begin with, SNG will take time to manufacture and distribute.

To over come this short-term supply, one possibility would be for several large hospitals to keep a cache and distribute SNG on a need-by-need basis to smaller hospitals in their area; but slowly as supply chain eases, smaller hospitals will want quicker access to their own supply.

For each hospital to stockpile, this scenario alone will increase demand beyond that of actual number of hospitalised patients.

Hope I've explained my reasoning clearly.

I am really only expecting headline results (promised by RM/RNS) and invitro results in January, preferably early January.
More detailed analysis will follow in due course.

Because we are all waiting - just speculating and looking at possible initial price zones.

For instance, if invitro data comes out first, price might find a temporary resistance at these levels: 250, 325, 390-400
Once through 250, this price zone can easily provide support.
Thereafter - would ideally be looking for price to make higher highs and higher lows.

Positive Sprinter results could easily blow through these levels.

Thank you Mattherhorn. Useful reminder of RM’s comment that data is king. Not long now...

;-)
Happy New Year to all SNG owners

Very happy for you and your family. And I wish you and your family well.

However, in consideration to others, entirelt irrelevant to this BB.

I agree with Doc - Woody's first para was somewhat SNG related and mildly interesting - then let down by unnecessary info.

JSP: Please don't encourage Woody to include unnecessary "information".

Cmww

Very sorry to hear about your girlfriend’s hearing loss. I had not known this was one of the long Covid symptom.

Unfortunately, as she has mild symptoms, she s unlikely to have qualified for SNG001 - but it does raise the question about the SNG0016 home trial - what data might we have had if we had a larger data set and also measured long covid

Thanks Ndn And Matml.
Missed the original post.